Molecular Targeted Therapy
"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
| Descriptor ID |
D058990
|
| MeSH Number(s) |
E02.319.574
|
| Concept/Terms |
Molecular Targeted Therapy- Molecular Targeted Therapy
- Molecular Targeted Therapies
- Targeted Therapies, Molecular
- Targeted Therapy, Molecular
- Therapies, Molecular Targeted
- Therapy, Molecular Targeted
- Targeted Molecular Therapy
- Molecular Therapies, Targeted
- Molecular Therapy, Targeted
- Targeted Molecular Therapies
- Therapies, Targeted Molecular
- Therapy, Targeted Molecular
|
Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".
Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".
This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 6 | 6 |
| 2013 | 2 | 7 | 9 |
| 2014 | 2 | 9 | 11 |
| 2015 | 7 | 14 | 21 |
| 2016 | 4 | 12 | 16 |
| 2017 | 0 | 8 | 8 |
| 2018 | 1 | 7 | 8 |
| 2019 | 0 | 13 | 13 |
| 2020 | 3 | 6 | 9 |
| 2021 | 5 | 4 | 9 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.
-
PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma. Cancer Chemother Pharmacol. 2022 05; 89(5):643-653.
-
Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases. Int J Mol Sci. 2021 Dec 28; 23(1).
-
Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases. Int J Mol Sci. 2021 Oct 15; 22(20).
-
Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021 10 06; 22(11):105.
-
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-d and -?. Front Immunol. 2021; 12:718621.
-
In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
-
Novel Therapeutical Approaches to Managing Atherosclerotic Risk. Int J Mol Sci. 2021 Apr 28; 22(9).
-
Ceramide kinase regulates TNF-a-induced immune responses in human monocytic cells. Sci Rep. 2021 04 15; 11(1):8259.
-
The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. Cells. 2021 01 12; 10(1).
-
Probing RAS Function with Monobodies. Methods Mol Biol. 2021; 2262:281-302.